Dr. Kopetz on the Rationale and Primary Endpoints of the BEACON CRC Study in mCRC

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the rationale and primary endpoints of the BEACON CRC study in BRAFV600E–mutant metastatic colorectal cancer (mCRC).